Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 97


Development of predictive models for airflow obstruction in alpha-1-antitrypsin deficiency.

Castaldi PJ, DeMeo DL, Kent DM, Campbell EJ, Barker AF, Brantly ML, Eden E, McElvaney NG, Rennard SI, Stocks JM, Stoller JK, Strange C, Turino G, Sandhaus RA, Griffith JL, Silverman EK.

Am J Epidemiol. 2009 Oct 15;170(8):1005-13. doi: 10.1093/aje/kwp216. Epub 2009 Sep 2.


Determinants of airflow obstruction in severe alpha-1-antitrypsin deficiency.

Demeo DL, Sandhaus RA, Barker AF, Brantly ML, Eden E, McElvaney NG, Rennard S, Burchard E, Stocks JM, Stoller JK, Strange C, Turino GM, Campbell EJ, Silverman EK.

Thorax. 2007 Sep;62(9):806-13. Epub 2007 Mar 27.


IL10 polymorphisms are associated with airflow obstruction in severe alpha1-antitrypsin deficiency.

Demeo DL, Campbell EJ, Barker AF, Brantly ML, Eden E, McElvaney NG, Rennard SI, Sandhaus RA, Stocks JM, Stoller JK, Strange C, Turino G, Silverman EK.

Am J Respir Cell Mol Biol. 2008 Jan;38(1):114-20. Epub 2007 Aug 9.


α₁-Antitrypsin protease inhibitor MZ heterozygosity is associated with airflow obstruction in two large cohorts.

Sørheim IC, Bakke P, Gulsvik A, Pillai SG, Johannessen A, Gaarder PI, Campbell EJ, Agustí A, Calverley PM, Donner CF, Make BJ, Rennard SI, Vestbo J, Wouters EF, Paré PD, Levy RD, Coxson HO, Lomas DA, Hersh CP, Silverman EK.

Chest. 2010 Nov;138(5):1125-32. doi: 10.1378/chest.10-0746. Epub 2010 Jul 1.


Clarification of the risk of chronic obstructive pulmonary disease in α1-antitrypsin deficiency PiMZ heterozygotes.

Molloy K, Hersh CP, Morris VB, Carroll TP, O'Connor CA, Lasky-Su JA, Greene CM, O'Neill SJ, Silverman EK, McElvaney NG.

Am J Respir Crit Care Med. 2014 Feb 15;189(4):419-27. doi: 10.1164/rccm.201311-1984OC.


Genetic epidemiology of severe, early-onset chronic obstructive pulmonary disease. Risk to relatives for airflow obstruction and chronic bronchitis.

Silverman EK, Chapman HA, Drazen JM, Weiss ST, Rosner B, Campbell EJ, O'DONNELL WJ, Reilly JJ, Ginns L, Mentzer S, Wain J, Speizer FE.

Am J Respir Crit Care Med. 1998 Jun;157(6 Pt 1):1770-8.


Linkage analysis of alpha 1-antitrypsin deficiency: lessons for complex diseases.

Silverman EK, Mosley JD, Rao DC, Palmer LJ, Province MA, Elston RC, Weiss ST, Campbell EJ.

Hum Hered. 2001;52(4):223-32.


The prevalence of alpha-1 antitrypsin deficiency among patients found to have airflow obstruction.

Rahaghi FF, Sandhaus RA, Brantly ML, Rouhani F, Campos MA, Strange C, Hogarth DK, Eden E, Stocks JM, Krowka MJ, Stoller JK.

COPD. 2012 Aug;9(4):352-8. doi: 10.3109/15412555.2012.669433. Epub 2012 Apr 16. Erratum in: COPD. 2013 Aug;10(4):555. Brantly, Mark L [added]; Rouhani, Farshid [added]; Campos, Michael A [added].


Alpha-1-antitrypsin augmentation therapy in deficient individuals enrolled in the Alpha-1 Foundation DNA and Tissue Bank.

Tonelli AR, Rouhani F, Li N, Schreck P, Brantly ML.

Int J Chron Obstruct Pulmon Dis. 2009;4:443-52. Epub 2009 Dec 29.


Variability of pulmonary function in alpha-1-antitrypsin deficiency: clinical correlates.

Silverman EK, Pierce JA, Province MA, Rao DC, Campbell EJ.

Ann Intern Med. 1989 Dec 15;111(12):982-91.


Asthma and COPD in alpha-1 antitrypsin deficiency. Evidence for the Dutch hypothesis.

Eden E.

COPD. 2010 Oct;7(5):366-74. doi: 10.3109/15412555.2010.510159. Review.


Genome-wide linkage analysis of severe, early-onset chronic obstructive pulmonary disease: airflow obstruction and chronic bronchitis phenotypes.

Silverman EK, Mosley JD, Palmer LJ, Barth M, Senter JM, Brown A, Drazen JM, Kwiatkowski DJ, Chapman HA, Campbell EJ, Province MA, Rao DC, Reilly JJ, Ginns LC, Speizer FE, Weiss ST.

Hum Mol Genet. 2002 Mar 15;11(6):623-32.


Relationship between frequency, length, and treatment outcome of exacerbations to baseline lung function and lung density in alpha-1 antitrypsin-deficient COPD.

Vijayasaratha K, Stockley RA.

Int J Chron Obstruct Pulmon Dis. 2012;7:789-96. doi: 10.2147/COPD.S31797. Epub 2012 Nov 27.


α1-Proteinase inhibitor (human) in the treatment of hereditary emphysema secondary to α1-antitrypsin deficiency: number and costs of years of life gained.

Sclar DA, Evans MA, Robison LM, Skaer TL.

Clin Drug Investig. 2012 May 1;32(5):353-60. doi: 10.2165/11631920-000000000-00000.


A review of alpha-1 antitrypsin deficiency.

Ranes J, Stoller JK.

Semin Respir Crit Care Med. 2005 Apr;26(2):154-66. Review.


Rate of progression of lung function impairment in alpha1-antitrypsin deficiency.

Dawkins PA, Dawkins CL, Wood AM, Nightingale PG, Stockley JA, Stockley RA.

Eur Respir J. 2009 Jun;33(6):1338-44. doi: 10.1183/09031936.00061208. Epub 2009 Jan 22.


The protease inhibitor PI*S allele and COPD: a meta-analysis.

Dahl M, Hersh CP, Ly NP, Berkey CS, Silverman EK, Nordestgaard BG.

Eur Respir J. 2005 Jul;26(1):67-76. Review.


Lower FEV1 in non-COPD, nonasthmatic subjects: association with smoking, annual decline in FEV1, total IgE levels, and TSLP genotypes.

Masuko H, Sakamoto T, Kaneko Y, Iijima H, Naito T, Noguchi E, Hirota T, Tamari M, Hizawa N.

Int J Chron Obstruct Pulmon Dis. 2011;6:181-9. doi: 10.2147/COPD.S16383. Epub 2011 Mar 2.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk